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The few studies to examine the relationship between coronary artery disease (CAD) and outcomes in patients 
with heart failure and preserved ejection fraction (HF-PEF) 
have produced conflicting results. CAD was associated with 
higher all-cause mortality in a single-center study from the 
United States, which included 376 patients with HF-PEF 
(255 with CAD).1 In a retrospective analysis of the Coronary 
Artery Surgery Study (CASS) registry, among 284 patients 
with HF-PEF, the number of diseased coronary arteries 
was an independent predictor of survival (68 patients had 
no CAD).2 However, these findings contradict those of a 
Framingham cohort analysis and a multicenter, prospec-
tive European study where in both there was no difference 
in mortality between HF-PEF patients with and without 
CAD.3,4 Even less is known about the relationship between 
CAD and modes of cardiovascular mortality, such as sudden 
death, which to our knowledge has only been examined in a 
handful of previous studies.4–6
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Background—The aim of our study was to investigate the relationship between coronary artery disease (CAD), angina, and 
clinical outcomes in patients with heart failure and preserved ejection fraction enrolled in the irbesartan in patients with 
heart failure and preserved systolic function (I-Preserve) trial.
Methods and Results—The mean follow-up period for the 4128 patients enrolled in I-Preserve was 49.5 months. Patients 
were divided into 4 mutually exclusive groups according to history of CAD and angina: patients with no history of CAD 
or angina (n=2008), patients with no history of CAD but a history of angina (n=649), patients with a history of CAD but 
no angina (n=468), and patients with a history of CAD and angina (n=1003); patients with no known CAD or angina were 
the reference group. After adjustment for other prognostic variables using Cox proportional-hazard models, patients with 
CAD but no angina were found to be at higher risk of all-cause mortality (hazard ratio [HR], 1.58 [1.22–2.04]; P<0.01) 
and sudden death (HR, 2.12 [1.33–3.39]; P<0.01), compared with patients with no CAD or angina. Patients with CAD 
and angina were also at higher risk of all-cause mortality (HR, 1.29 [1.05–1.59]; P=0.02) and sudden death (HR, 1.83 
[1.24–2.69]; P<0.01) compared with the same reference group and had the highest risk of unstable angina or myocardial 
infarction (HR, 5.84 [3.43–9.95]; P<0.01).
Conclusions—Patients with heart failure and preserved ejection fraction and CAD are at higher risk of all-cause mortality 
and sudden death when compared with those without CAD.
Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT00095238.   
(Circ Heart Fail. 2015;8:717-724. DOI: 10.1161/CIRCHEARTFAILURE.114.002024.)
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The prognostic implications of symptomatic myocardial 
ischemia (ie, angina) in HF-PEF are also poorly defined. In 
some patients, myocardial ischemia occurs even in the absence 
of major epicardial CAD. This is especially likely in the pres-
ence of left ventricular hypertrophy, which is pathognomonic 
of the HF-PEF phenotype. Other factors such as coronary 
microvascular dysfunction may also precipitate angina and in 
1 single-center analysis of consecutive patients with HF-PEF 
referred for angiography, the proportion of patients report-
ing angina symptoms was similar in those with and without 
epicardial CAD.1,7 We, therefore, investigated the relationship 
between CAD, angina and a range of clinical outcomes in the 
irbesartan in patients with heart failure and preserved systolic 
function (I-Preserve) trial.8
Methods
The design, baseline characteristics, and results of I-Preserve are pub-
lished.8–10 Briefly, 4128 patients aged ≥60 years with a left ventricular 
ejection fraction (LVEF) ≥45%, current signs and symptoms of heart 
failure and corroborating evidence (relevant electrocardiographic, 
chest x-ray, or echocardiographic abnormalities) were randomized to 
300 mg once daily of irbesartan or placebo. Patients in New York 
Heart Association (NYHA) functional classes II to IV were eligible 
but those in class II were required to have had a hospitalization for 
heart failure within the previous 6 months. Ethics committees at each 
participating institute approved the trial and all patients provided 
written informed consent. The mean follow-up was of 49.5 months. 
No significant treatment difference was seen in the primary compos-
ite outcome of death from any cause or hospitalization for a cardio-
vascular cause, or in any of the prespecified secondary end points.
Investigators recorded details of heart failure cause and medical 
history, including stable angina pectoris, by checking boxes on the 
trial case report form. For the purposes of this retrospective analysis, 
patients with a history of CAD were defined as those with a history 
of previous myocardial infarction (MI), percutaneous coronary inter-
vention, coronary artery bypass grafting, or a primary ischemic cause 
as defined by investigators. Patients were divided into 4 mutually ex-
clusive groups; those without a history of CAD or angina, patients 
without a history of CAD but with a history of angina, patients with 
a history of CAD but no angina and those with a history of CAD and 
angina.
Clinical Outcomes
The 3 other groups were compared with the reference group of pa-
tients without a history of CAD or angina for the following clinical 
outcomes: all-cause death, cardiovascular death, sudden death, death 
because of HF, HF death or HF hospitalization (the predefined com-
posite HF end point in I-Preserve), HF hospitalization, fatal or non-
fatal MI, and the composite of MI or unstable angina (UA). Sudden 
death was defined as an unexpected death in a previously stable pa-
tient. Patients with sudden death had to have human contact in the 
24 hours preceding the event; those who had been out of contact for 
more prolonged periods were classified as unknown.11
Statistical Analysis
Baseline characteristics were described using percentages for cat-
egorical variables and mean with SDs for continuous variables. The 
1-way ANOVA test was used to compare continuous variables except 
where data were not normally distributed where the Welch test was 
used. The χ2 test was used to compare categorical variables.
The relationships between a history of CAD, angina, and out-
comes were assessed using Kaplan–Meier cumulative event survival 
curves and Cox proportional-hazard regression analyses. In sensitiv-
ity analyses, we examined the impact of the competing risk of all-
cause mortality on the cumulative incidence of HF hospitalizations 
and the competing risk of noncardiovascular death on cardiovascular 
death. In both analyses, no substantial differences were found be-
tween the competing risks approach and the Kaplan–Meier approach 
(data not shown). For consistency, Kaplan–Meier estimates are pre-
sented.12,13 Published predictors of fatal and nonfatal outcomes in 
I-Preserve were used in the multivariable analyses.11,14 The variables 
adjusted were N-terminal pro-brain natriuretic peptide (NT-proBNP; 
log) levels, age, recent HF hospitalization, diabetes mellitus, neutro-
phil count (log), ejection fraction, chronic obstructive pulmonary dis-
ease or asthma, glomerular filtration rate, disease-specific quality of 
life measured using the Minnesota living with HF questionnaire, and 
heart rate; the presence of left bundle branch block was also included 
in the analysis of sudden death. The Cox proportional-hazard survival 
analyses used a conventional 2-tailed P<0.05 as the statistical level of 
significance. All statistical analyses were performed using Stata ver-
sion 13, Stata Corp, College Station, TX and IBM SPSS Statistics for 
Mac, version 22.0. Armonk, NY.
Results
Of 4128 patients in I-Preserve, 2657 (64% of the total) had no 
recorded history of CAD; 649 (24%) of these patients without 
CAD had a history of angina. Of the 1471 patients (36% of 
the total) with a history of CAD, 1003 (68%) had a history 
of angina.
Baseline Characteristics
Baseline characteristics stratified by history of angina and 
CAD are presented in Table 1.
Comparison of Patients With and Without a History 
of CAD
Patients with a history of CAD were more likely to be men 
(52% versus 33%), have a history of diabetes mellitus (32% 
versus 25%), a higher median NT-proBNP level (449 versus 
282 pg/mL), and a slightly lower mean LVEF (58% versus 
61%). They were less likely to have a history of hyperten-
sion (82% versus 92%) or atrial fibrillation (13% versus 
18%). Patients with a history of CAD were more likely to be 
in NYHA functional class III or IV (82% versus 77%) than 
those without a history of CAD. However, their quality of life, 
as assessed by the Minnesota living with HF questionnaire, 
was similar (score of 42 versus 43). Patients with CAD were 
also more likely to be prescribed a statin (41% versus 23%) 
or antiplatelet agent (78% versus 48%) at baseline. There was 
no significant difference in diuretic use in patients with and 
without CAD (82% versus 83%).
Patients With No History of CAD: Angina Versus 
No Angina
Patients without a history of CAD but a history of angina were 
more likely to be women (70% versus 66%), have a history of 
hypertension (96% versus 91%), and have a lower median NT-
proBNP level (241 versus 298 pg/mL) than patients with nei-
ther a history of CAD nor angina. They were less likely to have 
diabetes mellitus (22% versus 26%) or atrial fibrillation (12% 
versus 20%). Their quality of life, as assessed by the Minnesota 
living with HF questionnaire, was worse (score of 46 versus 
41). The mean LVEF was similar in the 2 groups (60% versus 
61%). Patients without a history of CAD but a history of angina 
were also more likely to be prescribed a diuretic (89% versus 
82%) or antiplatelet agent (65% versus 42%) at baseline. The 
use of statins was similar in the 2 groups (23% versus 23%).
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Patients With a History of CAD: Angina Versus No 
Angina
Patients with a history of CAD and angina were more likely to 
be women (49% versus 46%) and had a slightly lower mean 
LVEF (57% versus 59%), worse quality of life score (45 ver-
sus 41), and less frequent previous coronary revascularization 
(35% versus 43%) than patients with CAD but no angina. They 
were also less likely to have a history of diabetes mellitus (29% 
versus 38%) or atrial fibrillation (12% versus 15%); however, 
the proportion of patients with a history of hypertension (82% 
versus 81%) was similar in the 2 groups. The proportion of 
patients in NYHA functional class III or IV (81% versus 82%) 
and the median NT-proBNP level (455 versus 455 pg/mL) was 
also similar in the 2 groups. Patients with CAD and angina 
were more likely to be prescribed a diuretic (84% versus 76%) 
or antiplatelet agent (81% versus 74%) but less likely to be 
prescribed a statin at baseline (37% versus 49%).
Clinical Outcomes
Mortality
In I-Preserve, cardiovascular death accounted for 70% of all 
deaths. Sudden death accounted for 38% of all cardiovascular 
deaths (n=231); approximately double the number of patients 
with death because of HF (20% of all cardiovascular deaths, 
n=125).
In patients without a history of CAD, those with and with-
out angina had a similar risk of death from any cause, cardio-
vascular death and sudden death (Tables 2 and 3; Figure 1). 
Table 1. Baseline Characteristics of Patients Stratified by Severity of History of Angina Pectoris and CAD
Variable
No CAD
No Angina
(n=2008)
No CAD
Angina
(n=649)
CAD
No Angina
(n=468)
CAD
Angina
(n=1003) P Value
Age, y 71.8±7.1 71.0±6.7 72.6±7.0 71.3±6.8 <0.01
Women, n (%) 1330 (66) 455 (70) 214 (46) 492 (49) <0.01
White, n (%) 1835 (91) 634 (98) 435 (93) 955 (95) <0.01
NYHA III/IV, n (%) 1563 (78) 492 (76) 385 (82) 817 (81) <0.01
Minnesota living with HF score 41.2 (21.0) 45.6 (18.5) 41.1 (21.9) 44.5 (20.9) <0.01
LVEF, % 60.6±9.5 60.1±8.5 58.6±9.4 57.0±8.1 <0.01
Systolic BP, mm Hg 137±15 137±13. 135±16 135±15 <0.01
Heart rate, beats per minute 71.9±10.8 71.3±9.5 70.9±10.6 70.8±10.1 0.02
BMI, kg/m2 30.0±5.6 29.4±4.8 29.3±5.1 29.2±4.9 <0.01
Medical history
  MI, n (%) 0 (0) 0 (0) 308 (66) 661 (66) <0.01
  PCI or CABG, n (%) 0 (0) 0 (0) 200 (43) 348 (35) <0.01
  Hypertension, n (%) 1823 (91) 622 (96) 380 (81) 825 (82) <0.01
  Diabetes mellitus, n (%) 520 (26) 145 (22) 179 (38) 290 (29) <0.01
  AF at baseline, n (%) 401 (20) 81 (12) 70 (15) 118 (12) <0.01
  Stroke or TIA, n (%) 178 (9) 56 (9) 61 (13) 104 (10) 0.03
  Pacemaker, n (%) 122 (6) 35 (5) 37 (8) 58 (6) 0.33
  ICD, n (%) 3 (0) 1 (0) 3 (1) 5 (0) 0.15
Laboratory measurements
  Anemia at baseline, n (%) 239 (13) 60 (9) 72 (16) 143 (15) <0.01
  Estimated GFR 72.5±23.1 72.8±19.8 70.4±21.3 73.4±23.3 0.13
  Median NT-proBNP concentrations, pg/mL* 298 (119–942) 241 (102–773) 455 (196–1196) 455 (188–1043) <0.01
Medication
  Diuretic, n (%) 1639 (82) 576 (89) 357 (76) 846 (84) <0.01
  ACE inhibitor, n (%) 438 (22) 167 (26) 139 (30) 289 (29) <0.01
  β-blocker, n (%) 1016 (51) 434 (67) 296 (63) 681 (68) <0.01
  CCB, n (%) 857 (43) 282 (44) 143 (31) 355 (36) <0.01
  Long-acting Nitrate, n (%) 186 (9) 245 (38) 135 (29) 542 (54) <0.01
  Antiplatelet, n (%) 843 (42) 422 (65) 344 (74) 807 (81) <0.01
  Statin, n (%) 459 (23) 150 (23) 229 (49) 372 (37) <0.01
Qualitative variables percentages and systolic BP reported as integers. ACE indicates angiotensin-converting enzyme; AF, atrial 
fibrillation; BMI, body mass index; BP, blood pressure; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CCB, calcium 
channel blocker; GFR, glomerular filtration rate; HF, heart failure; ICD, implantable cardioverter defibrillator; LVEF, left ventricular ejection 
fraction; MI, myocardial infarction; NT-proBNP, N-terminal probrain natriuretic peptide; NYHA, New York Heart Association class; PCI, 
percutaneous coronary intervention; and TIA, transient ischemic attack.
*NT-proBNP concentrations expressed as medians with first and third quartile values contained within parenthesis.
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Patients with a history of angina had a lower risk of death 
because of HF that was nominally statistically significant 
in the unadjusted analysis but not after adjustment for other 
prognostic variables in a multivariable analysis: hazard ratio 
(HR), 0.54, 0.24 to 1.21; P=0.14.
Patients with a history of CAD (with or without angina) 
were at higher risk of death from any cause compared with 
those without a history of CAD or angina in both adjusted and 
unadjusted analyses (Tables 2 and 3; Figure 1).
Patients with a history of CAD and angina were at higher 
risk of death from any cause (HR, 1.29 [1.05–1.59]; P=0.02), 
cardiovascular death (HR, 1.46 [1.14–1.86]; P<0.01), and 
sudden death (HR, 1.83 [1.24–2.69]; P<0.01), compared with 
those without a history of CAD or angina (Tables 2 and 3; 
Figure 1).
Patients with a history of CAD but no angina had the 
highest risk of death from any cause (HR, 1.58 [1.22–2.04]; 
P<0.01), cardiovascular causes (HR, 1.50 [1.10–2.06]; 
P=0.01), as well as the highest risk of sudden death (HR, 
2.12 [1.33–3.39]; P<0.01). They were not, however, at higher 
risk of death because of HF (HR, 0.66 [0.29–1.49]; P=0.32; 
Tables 2 and 3; Figure 1).
HF Outcomes
In patients without a history of CAD, those with and without 
angina had a similar risk of heart failure outcomes (Tables 2 
and 3; Figure 2). Patients with a history of angina had a lower 
risk of HF hospitalization that was nominally statistically sig-
nificant in the unadjusted analysis but not after adjustment for 
other prognostic variables in a multivariable analysis (HR, 
0.94 [0.70–1.25]; P=0.67).
Patients with a history of CAD (with or without angina) 
were at moderately higher risk of both HF hospitalization and 
the composite end point of HF death or HF hospitalization 
when compared with patients without a history of CAD or 
angina. However, following multivariable adjustment only 
the composite end point of HF death or HF hospitalization in 
patients with CAD and angina remained significant (HR, 1.26 
[1.03–1.54]; P=0.02; Tables 2 and 3; Figure 2).
Coronary Outcomes
Coronary events occurred infrequently in I-Preserve. Only 5% 
of the overall study sample were hospitalized for UA or MI 
during follow-up.
In patients without a history of CAD, those with angina 
had a higher risk of the composite outcome of UA or MI com-
pared with patients without CAD or angina. This relationship 
was strengthened after multivariable adjustment (HR, 2.20 
[1.10–4.37]; P=0.03). The risk of fatal or nonfatal MI was not 
increased in patients with a history of angina, even after mul-
tivariable adjustment (HR, 1.51 [0.66–3.43]; P=0.33; Tables 2 
and 3; Figure 2).
Patients with a history of CAD but no history of angina and 
patients with a history of CAD and angina both had a higher 
adjusted risk of UA or MI when compared with patients with 
no history of CAD or angina ([HR, 4.44 {2.31–8.54}; P<0.01] 
and [HR, 5.84 {3.43–9.95}; P<0.01], respectively). A simi-
lar finding was seen in relation to fatal or nonfatal MI after 
multivariable analysis ([HR, 2.75 {1.26–5.97}; P=0.01] and 
[HR, 5.14 {2.90–9.13}; P<0.01], respectively; Tables 2 and 
3; Figure 2).
Discussion
In our analysis of the 4128 patients with HF-PEF random-
ized in I-Preserve, angina was present in 68% of patients with 
CAD and 24% of those with no history of CAD. Patients 
with a history of CAD were at higher risk of death from any 
cause, which was driven by a higher rate of sudden death in 
particular.
The relatively high frequency of angina pectoris in 
patients without a history of CAD is consistent with an earlier 
single-center study of 376 patients hospitalized with HF-PEF 
in the United States.1 In that study, after discharge, all partici-
pants underwent angiography within 12 months and a similar 
Table 2. Clinical Outcomes According to History of Angina Pectoris and Coronary Disease (Univariate Analysis)
Group Comparison
No CAD
No Angina
(n=2008)
No CAD
Angina
(n=649)
CAD
No Angina
(n=468)
CAD
Angina
(n=1003)
No CAD/Angina vs No 
CAD/No Angina
CAD/No Angina vs No 
CAD/No Angina
CAD/Angina vs No CAD/
No Angina
No.  
(event rate)
No.  
(event rate)
No. 
(event rate)
No.  
(event rate) HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value
Mortality outcomes
  All-cause death 379 (46.0) 110 (39.5) 153 (86.2) 239 (59.7) 0.85 (0.69–1.05) 0.14 1.90 (1.57–2.29) <0.01 1.30 (1.10–1.52) <0.01
  CV death 243 (29.5) 83 (29.8) 104 (58.6) 183 (45.7) 1.00 (0.78–1.29) 0.97 2.00 (1.59–2.52) <0.01 1.55 (1.28–1.88) <0.01
  Sudden death 83 (10.1) 31 (11.1) 43 (24.2) 74 (18.5) 1.10 (0.73–1.66) 0.66 2.42 (1.67–3.49) <0.01 1.83 (1.34–2.50) <0.01
  Deaths because of HF 61 (7.4) 10 (3.6) 18 (10.1) 36 (9.0) 0.48 (0.25–0.95) 0.03 1.38 (0.81–2.33) 0.24 1.22 (0.81–1.84) 0.35
HF outcomes
  HF death/HFH 390 (51.5) 106 (41.1) 126 (77.8) 244 (67.7) 0.81 (0.65–1.00) 0.05 1.49 (1.22–1.82) <0.01 1.31 (1.12–1.54) <0.01
  HFH 312 (41.2) 81 (31.4) 88 (54.3) 180 (49.9) 0.78 (0.61–0.99) 0.04 1.29 (1.02–1.64) 0.03 1.21 (1.00–1.45) 0.05
Coronary outcomes
  Fatal/nonfatal MI 33 (4.0) 14 (5.1) 25 (14.3) 77 (19.8) 1.26 (0.68–2.36) 0.46 3.52 (2.09–5.92) <0.01 4.89 (3.25–7.35) <0.01
  UA/MI 41 (5.0) 20 (7.3) 33 (19.1) 100 (26.0) 1.46 (0.86–2.49) 0.17 3.75 (2.37–5.93) <0.01 5.16 (3.59–7.43) <0.01
Event rates expressed as per 1000 patient-years. CAD indicates coronary artery disease; CI, confidence interval; CV, cardiovascular; HF, heart failure; HFH, HF 
hospitalization; HR, hazard ratio; MI, myocardial infarction; and UA, unstable angina.
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prevalence of angina was noted irrespective of whether signifi-
cant epicardial CAD was detected. Factors such as left ventric-
ular hypertrophy and coronary microvasculature dysfunction 
may contribute to angina symptoms in patients without epi-
cardial CAD.7,15 An alternative explanation is that in our study 
at least some of these patients simply had undiagnosed CAD; 
Table 3. Clinical Outcomes According to History of Angina Pectoris and CAD (Multivariable Analysis)
Group Comparison
No CAD/Angina vs No  
CAD/No Angina
CAD/No Angina vs No  
CAD/No Angina
CAD/Angina vs No  
CAD/No Angina
HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value
Mortality outcomes
  All-cause death* 0.95 (0.73–1.25) 0.72 1.58 (1.22–2.04) <0.01 1.29 (1.05–1.59) 0.02
  CV death* 1.11 (0.82–1.52) 0.50 1.50 (1.10–2.06) 0.01 1.46 (1.14–1.86) <0.01
  Sudden death† 1.08 (0.64–1.85) 0.77 2.12 (1.33–3.39) <0.01 1.83 (1.24–2.69) <0.01
  Deaths because of HF* 0.54 (0.24–1.21) 0.14 0.66 (0.29–1.49) 0.32 1.08 (0.64–1.83) 0.78
Heart failure outcomes*
  HF death/HFH 0.93 (0.72–1.20) 0.56 1.19 (0.91–1.55) 0.20 1.26 (1.03–1.54) 0.02
  HFH 0.94 (0.70–1.25) 0.67 1.03 (0.75–1.40) 0.87 1.12 (0.89–1.41) 0.35
Coronary outcomes*
  Fatal/nonfatal MI 1.51 (0.66–3.43) 0.33 2.75 (1.26–5.97) 0.01 5.14 (2.90–9.13) <0.01
  MI/UA 2.20 (1.10–4.37) 0.03 4.44 (2.31–8.54) <0.01 5.84 (3.43–9.95) <0.01
CAD indicates coronary artery disease; CI, confidence interval; CV, cardiovascular; HF, heart failure; HFH, HF hospitalization; HR, hazard ratio; 
MI, myocardial infarction; NT-proBNP, N-terminal probrain natriuretic peptide; and UA, unstable angina.
*Adjusted for were NT-proBNP (log) concentration, age, recent HFH, diabetes mellitus, neutrophil count (log), ejection fraction, chronic 
obstructive pulmonary disease or asthma, glomerular filtration rate, quality of life score, and heart rate.
†Adjusted for were NT-proBNP (log) concentration, age, recent HFH, diabetes mellitus, neutrophil count (log), ejection fraction, chronic 
obstructive pulmonary disease or asthma, glomerular filtration rate, quality of life score, heart rate, and left bundle branch block on ECG.
Figure 1. Kaplan–Meier curves illustrating relationship between history of angina, coronary artery disease (CAD), and outcomes. A, All-
cause death, (B) cardiovascular (CV) death, (C) sudden death, and (D) deaths because of heart failure (HF). 
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we do not know what proportion had coronary angiography 
but 3% did experience an acute MI or an episode of UA after 
randomization. Another consideration is that undiagnosed 
CAD, rather than HF-PEF per se, could have been the cause 
of symptoms in a proportion of patients enrolled in I-Preserve, 
given that the diagnosis of HF-PEF is difficult. Although most 
patients with no history of CAD but with a history of angina 
were in NYHA functional class III or IV (and these patients 
also had significantly reduced quality of life as measured by 
the Minnesota questionnaire), they also had the lowest base-
line NT-proBNP level with levels that were entirely normal in 
over a quarter of patients.
Baseline Characteristics
Patients with CAD (with or without a history of angina) had 
more advanced heart failure as evidenced by the higher fre-
quency of NYHA class III or IV symptoms, slightly lower 
mean LVEF and higher median NT-proBNP level. However, 
disease-specific quality of life measured with the Minnesota 
living with HF questionnaire was not significantly different 
from those without CAD. Conversely, a history of angina 
pectoris was associated with worse quality of life, irrespec-
tive of CAD history. This finding suggests that treating angina 
in patients with HF-PEF has the potential to improve heart 
failure–related quality of life.
Relationship Between CAD, Angina, and Mortality
The association between CAD and all-cause mortality has 
been extensively investigated in HF-REF but not HF-PEF. 
CAD was an independent predictor of higher all-cause mortal-
ity in the aforementioned single-center study of 376 patients 
hospitalized with HF-PEF (adjusted HR, 1.71 [1.03–2.98]; 
P=0.04) and in the 284 patients with HF-PEF in the CASS 
registry.1,2 In the CASS registry, HF-PEF patients with absent, 
moderate, or triple-vessel CAD had respective 6-year survival 
rates of 92%, 83%, and 68% (P=0.0001).2 However, patients 
with HF-PEF in a cohort from the Framingham Heart Study 
(n=220) did not demonstrate a difference in survival related to 
the presence of CAD and this lack of association was also seen 
in a prospective multicenter study of 320 patients hospital-
ized with HF-PEF in France (adjusted HR, 0.93 [0.69–1.26]; 
P=0.65).3,4 The reasons behind these conflicting results are not 
clear but small sample sizes, heterogeneous patient cohorts, 
and differences in the variables used to adjust survival may 
all contribute. In this study, patients with CAD, irrespective 
of angina, had higher risk of death than those without CAD or 
angina, even after extensive adjustment for other prognostic 
variables, including NT-proBNP.
The more important finding in I-Preserve was that the 
higher mortality in patients with CAD was because of a much 
higher (double) risk of sudden death. Although the highest 
Figure 2. Kaplan–Meier curves illustrating relationship between history of angina, coronary artery disease (CAD) and outcomes.  
A, Heart failure (HF) death/HF hospitalization, (B) HF hospitalization, (C) fatal or nonfatal myocardial infarction (MI), and (D) MI or 
unstable angina (UA).
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risk occurred in patients with a history of CAD but no angina 
(HR, 2.12 [1.33–3.39]; P<0.01), the HR was not significantly 
different to that in patients with CAD and angina (HR, 1.83 
[1.24–2.69]; P<0.01). Presumably, therefore, by causing 
myocardial ischemia (or infarction), underlying CAD led to 
higher mortality rates in HF-PEF by precipitating lethal ven-
tricular arrhythmias, although other causes of sudden death 
can occur (eg, a large MI, stroke, or rupture of an abdominal 
aortic aneurysm).
Two smaller, multicenter, retrospective analyses of 
patients discharged from hospital with a diagnosis of HF-PEF 
(n=320 and n=787, respectively) also showed that CAD was 
associated with a higher risk of sudden death.4,5
Although HF-PEF patients with CAD are at increased 
risk of sudden death, the absolute rate is low (≈2% per year) 
and the potential role of implantable cardioverter defibrilla-
tor therapy unclear, especially as coronary revascularization 
might also ameliorate this risk (see below). One planned 
study of implantable loop recorders in patients with HF-PEF 
designed to examine the frequency of significant ventricular 
arrhythmias will not fully address this question as patients 
with significant CAD or a recent MI will be excluded (http://
clinicaltrials.gov/ct2/show/NCT01989299).
The Relationship Between CAD,  
Angina, and UA/MI
Patients with CAD and angina had the highest risk of UA/
MI (HR, 5.84 [3.43–9.95]; P<0.01) when compared with 
those with no history of CAD or angina. However, the HR in 
the former group was not significantly different from that in 
patients with CAD but no history of angina (HR, 4.44 [2.31–
8.54]; P<0.01). The strength of the association in the CAD 
and angina group was likely attenuated by our inability to dif-
ferentiate patients with past and current angina. In a recent 
analysis of the Candesartan in Heart Failure Assessment of 
Reduction in Mortality and Morbidity (CHARM) program, 
patients with CAD and current angina were almost 3 times 
as likely to experience UA/MI end point (adjusted HR, 2.75 
[1.88–4.01]; P<0.01) compared with patients with CAD but 
no history of angina.16 However, in CHARM there was no sig-
nificant association between past angina and UA/MI.
Clearly, both I-Preserve and CHARM-Preserved suggest 
new studies are needed to establish whether specific medical 
therapies or coronary revascularization have a role to play in 
reducing adverse events in patients with HF-PEF and CAD, 
whether or not they have angina. Two relatively small retro-
spective analyses assessing the role of coronary revascular-
ization in these patients have produced conflicting results. 
A single-center study of 376 patients hospitalized with 
HF-PEF found complete revascularization was an indepen-
dent predictor of lower all-cause mortality.1 However, no such 
association was evident in the CASS registry although that 
study was conducted >20 years ago and it is not clear whether 
advances in medical therapy and coronary revascularization 
contributed to these conflicting findings.2
Our study has many limitations. This was a retrospec-
tive analysis that only included patients aged ≥60 years and 
excluded patients with additional comorbidities, such as resis-
tant hypertension, significant renal dysfunction, and anemia.8,9 
Therefore, our findings may not be representative of a real-
life cohort and cannot be generalized to all patients with 
HF-PEF, particularly younger patients. The history of angina 
was dependent on investigator-reported history. Also, patients 
in I-Preserve did not undergo routine angiography and it is 
possible that patients with CAD may have been misclassified 
(or vice versa); several studies have demonstrated the limita-
tions of noninvasive assessment in accurately establishing HF 
cause.17,18
In summary, patients with CAD and HF-PEF have evi-
dence of more advanced HF, whereas patients with angina 
and HF-PEF experience poorer quality of life, irrespective of 
the underlying cause. The risk of sudden death is significantly 
higher in patients with CAD and our findings suggest that 
specific interventions such as coronary revascularization or 
implantable cardioverter defibrillator therapy could improve 
outcomes in HF-PEF, although this hypothesis needs to be 
tested in prospective randomized trials.
Disclosures
None.
References
 1. Hwang SJ, Melenovsky V, Borlaug BA. Implications of coronary ar-
tery disease in heart failure with preserved ejection fraction. J Am Coll 
Cardiol. 2014;63(25 pt A):2817–2827. doi: 10.1016/j.jacc.2014.03.034.
 2. Judge KW, Pawitan Y, Caldwell J, Gersh BJ, Kennedy JW. Congestive 
heart failure symptoms in patients with preserved left ventricular sys-
tolic function: analysis of the CASS registry. J Am Coll Cardiol. 
1991;18:377–382.
 3. Lee DS, Gona P, Vasan RS, Larson MG, Benjamin EJ, Wang TJ, Tu JV, 
Levy D. Relation of disease pathogenesis and risk factors to heart failure 
with preserved or reduced ejection fraction: insights from the Framingham 
heart study of the National Heart, Lung, and Blood Institute. Circulation. 
2009;119:3070–3077. doi: 10.1161/CIRCULATIONAHA.108.815944.
 4. Rusinaru D, Houpe D, Szymanski C, Lévy F, Maréchaux S, Tribouilloy 
C. Coronary artery disease and 10-year outcome after hospital admission 
for heart failure with preserved and with reduced ejection fraction. Eur J 
Heart Fail. 2014;16:967–976. doi: 10.1002/ejhf.142.
 5. Adabag S, Smith LG, Anand IS, Berger AK, Luepker RV. Sudden cardiac 
death in heart failure patients with preserved ejection fraction. J Card 
Fail. 2012;18:749–754. doi: 10.1016/j.cardfail.2012.08.357.
 6. Al-Khatib SM, Shaw LK, O’Connor C, Kong M, Califf RM. Incidence 
and predictors of sudden cardiac death in patients with diastolic 
heart failure. J Cardiovasc Electrophysiol. 2007;18:1231–1235. doi: 
10.1111/j.1540-8167.2007.00957.x.
 7. Camici PG, d’Amati G, Rimoldi O. Coronary microvascular dysfunction: 
mechanisms and functional assessment. Nat Rev Cardiol. 2015;12:48–
62. doi: 10.1038/nrcardio.2014.160.
 8. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile 
MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A; 
I-PRESERVE Investigators. Irbesartan in patients with heart failure and 
preserved ejection fraction. N Engl J Med. 2008;359:2456–2467. doi: 
10.1056/NEJMoa0805450.
 9. Carson P, Massie BM, McKelvie R, McMurray J, Komajda M, Zile M, 
Ptaszynska A, Frangin G; I-PRESERVE Investigators. The irbesartan 
in heart failure with preserved systolic function (I-PRESERVE) trial: 
rationale and design. J Card Fail. 2005;11:576–585. doi: 10.1016/j.
cardfail.2005.06.432.
 10. McMurray JJ, Carson PE, Komajda M, McKelvie R, Zile MR, Ptaszynska 
A, Staiger C, Donovan JM, Massie BM. Heart failure with preserved 
ejection fraction: clinical characteristics of 4133 patients enrolled in the 
I-PRESERVE trial. Eur J Heart Fail. 2008;10:149–156. doi: 10.1016/j.
ejheart.2007.12.010.
 11. Adabag S, Rector TS, Anand IS, McMurray JJ, Zile M, Komajda M, 
McKelvie RS, Massie B, Carson PE. A prediction model for sudden car-
diac death in patients with heart failure and preserved ejection fraction. 
Eur J Heart Fail. 2014;16:1175–1182. doi: 10.1002/ejhf.172.
 by guest on June 29, 2017
http://circheartfailure.ahajournals.org/
D
ow
nloaded from
 
724  Circ Heart Fail  July 2015
 12. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of 
a competing risk. J Am Stat Assoc 1999;94:496–509.
 13. Gray B. Subdistribution analysis of competing risks. The cmprsk library 
(v 2.2–6). 2013. http://cran.r-project.org. Accessed April 22, 2015.
 14. Komajda M, Carson PE, Hetzel S, McKelvie R, McMurray J, 
Ptaszynska A, Zile MR, Demets D, Massie BM. Factors associated 
with outcome in heart failure with preserved ejection fraction: findings 
from the Irbesartan in Heart Failure with Preserved Ejection Fraction 
Study (I-PRESERVE). Circ Heart Fail. 2011;4:27–35. doi: 10.1161/
CIRCHEARTFAILURE.109.932996.
 15. Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved 
ejection fraction: comorbidities drive myocardial dysfunction and re-
modeling through coronary microvascular endothelial inflammation. J 
Am Coll Cardiol. 2013;62:263–271. doi: 10.1016/j.jacc.2013.02.092.
 16. Badar AA, Perez-Moreno AC, Hawkins NM, Brunton AP, Jhund PS, 
Wong CM, Solomon SD, Granger CB, Yusuf S, Pfeffer MA, Swedberg 
K, Gardner RS, Petrie MC, McMurray JJ. Clinical characteristics and 
outcomes of patients with angina and heart failure in the CHARM 
(Candesartan in Heart Failure Assessment of Reduction in Mortality 
and Morbidity) Programme. Eur J Heart Fail. 2015;17:196–204. doi: 
10.1002/ejhf.221.
 17. Cowie MR, Wood DA, Coats AJ, Thompson SG, Poole-Wilson PA, 
Suresh V, Sutton GC. Incidence and aetiology of heart failure; a popula-
tion-based study. Eur Heart J. 1999;20:421–428.
 18. Fox KF, Cowie MR, Wood DA, Coats AJ, Gibbs JS, Underwood SR, 
Turner RM, Poole-Wilson PA, Davies SW, Sutton GC. Coronary artery 
disease as the cause of incident heart failure in the population. Eur Heart 
J. 2001;22:228–236. doi: 10.1053/euhj.2000.2289.
CLINICAL PERSPECTIVE
The few previous studies to investigate the relationship between coronary artery disease (CAD) and all-cause mortality in 
patients with heart failure and preserved ejection fraction (HF-PEF) have produced conflicting results. This may be a reflec-
tion of small sample sizes, heterogeneous patient cohorts, and differences in the variables used to adjust survival. In this 
analysis of >4000 patients in the irbesartan in heart failure with preserved systolic function (I-Preserve) trial, patients with 
a history of CAD had a higher risk of death compared with those without CAD or angina. The higher mortality overall in 
patients with CAD was because of a much higher (double) risk of sudden death. We also found a surprisingly high prevalence 
of angina in patients without a history of CAD. This finding is consistent with a smaller single-center analysis of consecutive 
patients with HF-PEF referred for angiography where the proportion of patients reporting angina was similar in those with 
and without epicardial CAD. It suggests that additional factors such as left ventricular hypertrophy and coronary microvas-
culature dysfunction may contribute to the symptom of angina in patients with HF-PEF. Patients with angina experienced 
worse quality of life, irrespective of CAD history. Our findings suggest that treating angina in patients with HF-PEF has the 
potential to improve heart failure–related quality of life. Similarly, specific interventions such as coronary revasculariza-
tion might improve outcomes in patients with CAD and HF-PEF, although this hypothesis needs to be tested in prospective 
randomized trials.
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